Metabolically associated steatotic liver disease and the possibilities of using antihypertensive and hypolipidemic medications

Metabolically associated steatotic liver disease (MASLD) is one of the most common liver pathologies. Metabolically associated steatotic liver disease is closely linked to metabolic syndrome, including obesity, type 2 diabetes, dyslipidemia, and arterial hypertension, making it not only a gastroenterological issue but also a significant aspect of cardiometabolic diseases. An important task is finding effective treatments aimed at improving the condition of such patients. In recent years, antihypertensive and hypolipidemic drugs have gained attention as potential means for correcting the disorders associated with MASLD. This article analyzes the impact of these drugs on disease progression, considering their effects on lipid profiles, blood pressure, inflammation, and liver fibrosis. Various classes of antihypertensive agents, such as ACE inhibitors, angiotensin receptor blockers, and calcium channel blockers, as well as hypolipidemic drugs, including statins, fibrates, and omega-3 fatty acids, are discussed. Clinical data evaluation indicates that combined therapy with antihypertensive and hypolipidemic drugs may positively affect the reduction of steatosis, inflammation, and liver fibrosis, while also improving the cardiometabolic profile of patients. However, further studies are needed to develop optimal treatment regimens and more accurately determine the effectiveness and safety of these drugs in the context of metabolically associated steatotic liver disease.